Programme Category
Programme Name
Programme Description
IHI JU is based on the idea that interdisciplinary and cross-sector collaboration will enable perspective and breakthrough innovations in healthcare, including the pharmaceutical industry but also new fields such as biopharmaceuticals, medical technologies and biotechnologies.
Identifier Code
Call
Summary
With a view to harnessing new science and technologies, this topic aims to fund pre-competitive research and innovation for novel tools, methods and technologies that will foster the development of health innovations to prevent, intercept, diagnose, treat, and manage diseases and enable recovery more efficiently.
Accordingly, applicants must assemble a collaborative public-private partnership consortium reflecting the integrative and cross-sectoral nature of IHI JU, that is capable of addressing the challenge(s) and scope of the IHI JU Specific Objective 1 ‘contribute towards a better understanding of the determinants of health and priority disease areas’, as defined in IHI JU’s legal basis and described in more detail in the IHI JU SRIA.
Detailed Call Description
Applicants should consider the following points in their proposals:
a) address an unmet public health need based on at least one of the below:
- the high burden of the disease for patients and/or society due to its severity and/or the number of people affected by it;
- the high economic impact of the disease for patients and society;
- the transformational nature of the potential results on innovation processes where projects are not focussed on individual disease areas (e.g. health data analytics);
b) demonstrate the ability to translate research into innovative solutions that can be integrated/implemented into the healthcare ecosystem (taking into consideration the fragmented nature of European healthcare systems) and/or in industrial processes;
c) carry out a landscape analysis to avoid unnecessary overlap and duplication of efforts with existing initiatives/projects and to identify potential synergies and complementarities with the relevant ones. The proposal should include a plan on how to synergise with these identified initiatives.
When applicable, proposals should consider relevant aspects of patient-centricity, with the help of the most suitable health technologies and/or social innovations, taking demographic trends into account as relevant.
In their proposals, applicants are expected to perform activities at scale that consider the different innovation cycles of the pharmaceutical and medical technology industries and drive concrete and transformational outcomes, in line with the first IHI JU General Objective. In particular, the topic welcomes integrated pre competitive activities, including demonstration pilots, that could accelerate and improve the discovery, development and piloting of methods and strategies that facilitate the uptake of evidence-based practice and research outcomes into regular use (e.g. translation of results, deployment, uptake and piloting use in healthcare of novel treatments and healthcare solutions).
If applicable, applicants are expected to consider the potential regulatory impact of the anticipated project’s outputs, and, as relevant, develop a regulatory strategy and interaction plan for generating appropriate evidence and for engaging with regulators and other bodies in a timely manner, e.g. EU national competent authorities, notified bodies for medical devices and in-vitro diagnostic devices, health technology assessment (HTA) agencies, and the European Medicines Agency (EMA) through existing opportunities for regulatory support services, such as the Innovation Task Force and qualification advice.
As relevant, consideration should be given to the Health Data Access Bodies established under the European Health Data Space Regulation in the context of secondary use of data.
Applicants are strongly encouraged to consider relevant measures to provide open access to project generated outputs such as standards, data sets and other research results and, if relevant, share evidence on their clinical utility and economic aspects (efficiency).
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
Expected contribution of IHI per project: €8,000,000
For all the above topics applicant consortia must ensure that at least 45% of the action’s eligible costs and costs for the action related additional activities are provided by in-kind contributions to operational activities (‘IKOP’), financial contributions (‘FC’s), or in-kind contributions to additional activities (‘IKAA’). IKOP and FCs may be contributed by the constituent and affiliated entities of both the private members and the contributing partners. IKAA may be contributed by constituent and affiliated entities of the private members only. Contributing partners and their affiliated entities cannot contribute IKAA. However, while 45% is the threshold for eligibility, applicant consortia are strongly advised to aim for 50% to adequately support the ambition of the research in question and reflect the true public-private dimension as well as to provide a margin e.g. for unforeseen changes during the project lifetime.
Applicants should propose a project duration such that it matches project activities and expected outcomes and impacts.
Thematic Categories
- Education and training
- Health
- Industry
- Public Administration
- Research, Technological Development and Innovation
Eligibility for Participation
- Central Government
- Educational Institutions
- Legal Entities
- Local Authorities
- NGOs
- Non Profit Organisations
- Other Beneficiaries
- Private Bodies
- Researchers/Research Centers/Institutions
- State-owned Enterprises
- Trade Unions
Eligibility For Participation Notes
Described in Annex B of the Work Programme General Annexes and in the ”Conditions of the Calls for proposals and Calls management rules” section of the IHI JU Work Programme (WP)
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.